Efficacy measurement of ketorolac in reducing the severity of headache

Baratloo, Alireza; Amiri, Marzieh; Forouzanfar, Mohammad Mehdi; Hasani, Sadegh; Fouda, Samar; Negida, Ahmad

doi:10.15171/jept.2015.18

Document Type : Original Article

Authors

¹ Department of Emergency Medicine, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Emergency Medicine, Shahid Beheshti Hospital, Guilan University of Medical Sciences, Anzali, Iran

³ Faculty of Medicine, Shahid Beheshti Hospital,Shahid Beheshti University of Medical Sciences,Tehran, Iran

⁴ Faculty of medicine, Zagazig University, Zagazig, Egypt

https://doi.org/10.15171/jept.2015.18

Abstract

Objective: One of nonsteroidal anti-inflammatory drugs (NSAIDs) named as ketorolac is frequently used to relieve acute pain. Current study was conducted with the aim of ketorolac efficacy measurement as a pain killer agent for controlling the primary headache in emergency departments.
Methods: In this study, we enrolled 50 patients with primary headache who received 60 mg ketorolac intravenously as a slow infusion in about 10 minutes. Pain scores were evaluated with visual analog scale (VAS) on arrival and also 1 hour and 2 hours after ketorolac infusion. Statistical analysis was performed on collected data by using Wilcoxon and Mann-Whitney tests to assess the differences in VAS pain scores. Results: Decreasing the VAS more than 3 points from the arrival until 1 hour (P < 0.001), and more than 5 points from the arrival until 2 hours after ketorolac administration (P < 0.001) were seen. Those with history of analgesic use before admission in emergency department in comparison with the others did not accompany with more decline in pain score after 1 hour (P = 0.34) or 2 hours (P = 0.92).
Conclusion: It seems that ketorolac is assured, safe and well tolerated agent for pain control in patients presented with primary headache to the emergency departments. Based on the results achieved in this study, ketorolac illustrates its perceptible effects within 1 hour after administration that even more prominent after 2 hours.

Keywords

Main Subjects

Emergency medicine

References

1. Frishberg BM. Neuroimaging in presumed primary headache disorders. Semin Neurol 1997; 17(4): 373-82.

2. Davis CP, Torre PR, Williams C, Gray C, Barrett K, Krucke G, et al. Ketorolac versus meperidine-plus-promethazine treatment of migraine headache: evaluations by patients. Am J Emerg Med 1995; 13(2): 146-50.

3. Kasmaei HD, Baratloo A, Soleymani M. A 33-year-old woman with severe postpartum headache. Emergency 2013; 1(1): 27-9.

4. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review) report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55(6): 754-62. doi: 10.1212/WNL.55.6.754.

5. Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002; 137(10): 840-9. doi: 10.7326/0003-4819-137-10-200211190-00014.

6. Baratloo A, Negida A, El Ashal G, Behnaz N. Intravenous caffeine for the treatment of acute migraine: a pilot study. J Caffeine Res 2015; 5(3): 125-9. doi: 10.1089/jcr.2015.0004.

7. Pergolizzi JV, Taylor R, Raffa RB. Intranasal ketorolac as part of a multimodal approach to postoperative pain. Pain Pract 2015; 15(4): 378-88. doi: 10.1111/papr.12239.

8. Figueroa-Balderas L, Franco-Lopez F, Flores-Álvarez E, López-Rodríguez J, Vázquez-García J, Barba-Valadez C. [Reduction of omalgia in laparoscopic cholecystectomy: clinical randomized trial ketorolac vs ketorolac and acetazolamide]. Cir Cir 2013; 81(5):

368-72. [In Spanish].

9. Schleiffarth JR, Bayon R, Chang KE, Van Daele DJ, Pagedar NA. Ketorolac after free tissue transfer a comparative effectiveness study. Ann Otol Rhinol Laryngol 2014; 123(6): 446-9.

10. Iorno V, Landi L, Di Pasquale R, Cicenia S, Moschini V. Comparison of intravenous ketorolac with or without paracetamol in postoperative pain control following ambulatory surgery. Curr Med Res Opin 2013; 29(12): 1685-90. doi: 10.1185/03007995.2013.835256

11. Beltrán-Montoya J, Herrerias-Canedo T, Arzola-Paniagua A, Vadillo-Ortega F, Dueñas-Garcia OF, Rico-Olvera H. A randomized, clinical trial of ketorolac tromethamine vs ketorolac trometamine plus complex B vitamins for cesarean delivery analgesia. Saudi J Anaesth 2012; 6(3): 207-12. doi: 10.4103/1658-354X.101209.

12. Buckley MM, Brogden RN. Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1990; 39(1): 86-109. doi: 10.2165/00003495-199039010-00008.

13. Catapano MS. The analgesic efficacy of ketorolac for acute pain. J Emerg Med 1996; 14(1): 67-75. doi: 10.1016/0736-4679(95)02052-7.

14. Innes G, Croskerry P, Worthington J, Beveridge R, Jones D. Ketorolac versus acetaminophen-codeine in the emergency department treatment of acute low back pain. J Emerg Med 1998; 16(4): 549-56. doi: 10.1016/S0736-4679(98)00044-4/

15. Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997; 53(1): 139-88.

16. Hamel E. Current concepts of migraine pathophysiology. Can J Clin Pharmacol 1999; 6 Suppl A: 9A-14A.

17. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001; 53(3): 167-78. doi: 10.1002/jemt.1081.

18. Kasmaei HD, Baratloo A, Nasiri Z, Soleymani M, Shirafkan A, Hamedi ZS. Report of nineteen cerebral vein thrombosis referrals to an emergency department: a case series and literature review. Arch Neurosci 2015; 2(2): e20552. doi: 10.5812/archneurosci.20552.

19. Alimohammadi H, Baratloo A, Abdalvand A, Rouhipour A, Safari S. Effects of pain relief on arterial blood o2saturation. Trauma Mon 2014; 19(1): e14034. doi: 10.5812/traumamon.14034.

20. Harden RN, Carter TD, Gilman CS, Gross AJ, Peters JR. Ketorolac in acute headache management. Headache 1991; 31(7): 463-64. doi:10.1111/j.1526-4610.1991.hed3107463.x

21. Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med 2003; 21(3): 173-5. doi: 10.1016/S0735-6757(02)42256-5.

22. Harden RN, Rogers D, Fink K, Gracely RH. Controlled trial of ketorolac in tension‐type headache. Neurology 1998; 50(2): 507-9. doi: 10.1212/WNL.50.2.507.

23. Harden RN, Gracely RH, Carter T, Warner G. The placebo effect in acute headache management: ketorolac, meperidine, and saline in the emergency department. Headache 1996; 36(6): 352-6. doi: 10.1046/j.1526-4610.1996.3606352.x.

24. Wright JM, Price SD, Watson WA. NSAID use and efficacy in the emergency department: single doses of oral ibuprofen versus intramuscular ketorolac. Ann Pharmacother 1994; 28(3): 309-12.

25. Davis CP, Torre PR, Schafer NC, Dave B, Bass B. Ketorolac as a rapid and effective treatment of migraine headache: evaluations by patients. Am J Emerg Med 1993; 11(6): 573-5. doi: 10.1016/0735-6757(93)90003-T.

26. Friedman BW, Garber L, Yoon A, Solorzano C, Wollowitz A, Esses D, et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology 2014; 82(11): 976-83. doi: 10.1212/WNL.0000000000000223.

27. Friedman BW, Adewunmi V, Campbell C, Solorzano C, Esses D, Bijur PE, et al. A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches. Ann Emerg Med 2013; 62(4): 311-18.e4. doi: 10.1016/j.annemergmed.2013.03.017.

Journal of Emergency Practice and Trauma

Efficacy measurement of ketorolac in reducing the severity of headache

References

References

Volume 2, Issue 1 - Serial Number 1
January 2016
Pages 21-24

Efficacy measurement of ketorolac in reducing the severity of headache

References

References

Volume 2, Issue 1 - Serial Number 1January 2016Pages 21-24

Volume 2, Issue 1 - Serial Number 1
January 2016
Pages 21-24